This deal aligns with GSK's focus on addressing the complications of obesity, while restocking its pipeline amid key patent expiries.

Halozyme Hypercon has signed an exclusive global collaboration and licence agreement with Oruka Therapeutics to develop ORKA-001 using Hypercon Technology.

When Eli Lilly's Lebanon campus is complete, it will manufacture several of the pharma's APIs and genetic medicines to serve US patients.

Daiichi Sankyo has entered into a collaboration with Paris-based Waiv intended at digital pathology biomarker discovery for an ADC programme.

Ginkgo Bioworks CEO Jason Kelly discusses the company’s work on autonomous labs and their impact on biopharma R&D.

Pharmaceutical Technology rounds up the key readouts from the 2026 Digestive Disease Week conference held in Chicago.

MSD has completed its acquisition of Terns Pharmaceuticals, expanding its pipeline of treatments for chronic myeloid leukaemia (CML).

Citius Oncology has secured up to $36.5m to accelerate the commercialisation of Lymphir, a recombinant fusion protein immune therapy.

Sunshine Lake Pharma, Lannett and its wholly owned subsidiary Lanexa Biologics have received FDA approval for Langlara.

Novo Nordisk is set to launch Ozempic, its oral GLP-1 receptor agonist pill for adults with type 2 diabetes, in the US.

Why does product loss occur in aseptic fill-finish, and how can a CDMO overcome material constraints to preserve as much drug product as possible?

As with its previous siRNA deal, Madrigal plans to explore whether gene-silencing could complement its lead drug Rezdiffra.